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Alcohol consumption is inversely associated with the
risk of developing chronic kidney disease
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1Department of Nephrology, University of Groningen, University Medical Center Groningen, Groningen, The Netherlands; 2Division of
General Medicine and Primary Care, Department of Medicine, Beth Israel Deaconess Medical Center, Boston, Massachusetts, USA;
3Department of Nutrition, Harvard School of Public Health, Boston, Massachusetts, USA; 4Department of Epidemiology, Harvard School
of Public Health, Boston, Massachusetts, USA; 5Channing Division of Network Medicine, Department of Medicine, Brigham and Women’s
Hospital, Harvard Medical School, Boston, Massachusetts, USA and 6Top Institute Food and Nutrition, Wageningen, The Netherlands
There are few reports of associations between alcohol
consumption and risk of chronic kidney disease (CKD). To
investigate this further, we studied 5476 participants aged
28–75 years in the Prevention of Renal and Vascular End-
Stage Disease (PREVEND) study, a prospective population-
based cohort, who were free of CKD at baseline (1997/1998).
Alcohol consumption was self-reported on a questionnaire
validated against serum high-density lipoprotein cholesterol.
The primary outcome was de novo CKD defined as a
combination of a creatinine–cystatin C–based estimated
glomerular filtration rate (eGFR) under 60ml/min per 1.73m2
and/or the mean of two consecutive 24-h urinary albumin
excretions over 30mg. During four serial follow-up
examinations (median 10.2 years until February 2012),
903 participants developed CKD. Compared with those
abstaining from alcohol, the multivariable-adjusted hazard
ratios (95% confidence interval) for CKD risk were 0.85
(0.69–1.04) for occasional (under 10g/week), 0.82 (0.69–0.98)
for light (10–69.9 g/week), 0.71 (0.58–0.88) for moderate
(70–210g/week), and 0.60 (0.42–0.86) for heavier (over
210g/week) alcohol consumers (significant trend). Similar
inverse associations for alcohol consumption were found
when CKD was defined as eGFR o60ml/min per 1.73m2 or
as 24-h urinary albumin excretion over 30mg. Thus, in this
population-based cohort, alcohol consumption was inversely
associated with the risk of developing CKD.
Kidney International (2015) 87, 1009–1016; doi:10.1038/ki.2014.414;
published online 14 January 2015
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Although alcohol consumption, particularly in moderation,
has consistently been linked to a lower risk of cardiovascular
disease1 and type 2 diabetes,2 its association with the risk of
chronic kidney disease (CKD) has received considerably less
attention. So far, longitudinal cohort studies that have exa-
mined the effect of alcohol consumption on the development
of CKD observed mostly inverse associations,3–5 although
some inconsistency exists.5,6
Most previous studies on alcohol and CKD risk relied on
serum creatinine–based equations to assess glomerular filtra-
tion rate (GFR), such as the Cockgroft–Gault7 or the Modification
of Diet in Renal Disease (MDRD),8 with uncertain validity in
general population cohorts with higher GFR.9,10 Further-
more, creatinine-based estimates to assess GFR are relatively
imprecise owing to variation in nonrenal determinants of
serum creatinine, a by-product of muscle breakdown. Such
nonrenal influences—for example, meat intake, lean body
mass, and muscle metabolism—may be related to alcohol
consumption, which may introduce a varying degree of mea-
surement bias in the estimation of GFR. A recently developed
and validated equitation that also uses serum cystatin C as
complementary filtration marker has been shown to be more
accurate for estimating GFR,11 and may thus be less sub-
jective to the aforementioned shortcomings.
Besides estimated GFR (eGFR), urinary albumin excretion
(UAE) can be used to supplement the classification of CKD.12
So far, only two prospective cohort studies have investigated
the relationship between alcohol intake and both com-
ponents of CKD, albeit separately, and with opposing
findings on albuminuria.4,5
Hence, we evaluated the association between alcohol con-
sumption and the risk of CKD among participants in a
population-based cohort study free of CKD at baseline and with
serial measurements of serum creatinine, serum cystatin C, and
UAE for a more optimal and integral definition of CKD.
RESULTS
Baseline characteristics of the study population according to
alcohol consumption categories are shown in Table 1.
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Consistent with prior studies, subjects who consumed more
alcohol were more likely to be male, current smokers, and
more highly educated. Because of the substantial difference in
gender across drinking categories, we additionally stratified
baseline characteristics by gender (Supplementary Table S1
online). To validate self-reported alcohol consumption at
baseline, we determined the relationship between alcohol
consumption categories and high-density lipoprotein
(HDL)-cholesterol. Mean serum HDL-cholesterol concentra-
tions increased with increasing alcohol consumption category
in both women and men (Table 2).
Alcohol consumption was fairly stable during follow-up.
For instance, alcohol consumption at the first (baseline) and
second examination (a median of 4.2 years later) was highly
correlated (r¼ 0.82; Po0.001; N¼ 5414). In addition, 3655
(67.5%) subjects who attended the second examination
reported the same alcohol category as the first examination,
and 5186 (95.8%) subjects were in the same or an adjacent
alcohol consumption category.
During a median follow-up of 10.2 years (interquartile
range, 6.2–11.4 years), a total of 903 participants developed
CKD (defined as a creatinine–cystatin C–based eGFR
Table 1 | Baseline characteristics according to alcohol consumption among 5476 participants of the PREVEND study










Participants, N (%) 5476 1285 (23.5) 860 (15.7) 1949 (35.6) 1121 (20.5) 261 (4.8)
Age (years) 48.4±11.7 50.2±12.6 47.4±12.5y 47.1±11.4y 48.8±10.7z 49.2±10.1 o0.001
Female, n (%) 2881 (52.6) 889 (69.2) 554 (64.4)* 928 (47.6)y 445 (39.8)y 65 (24.9)y o0.001
Smoking, n (%)
Never 1729 (31.7) 540 (42.3) 351 (41.0) 589 (30.3)z 213 (19.1)y 36 (13.8)y o0.001
Former 1985 (36.4) 372 (29.1) 287 (33.5) 761 (39.1) 477 (42.6) 88 (33.7)
Current o6 cigarettes/day 298 (5.5) 56 (4.4) 46 (5.4) 114 (5.9) 71 (6.3) 11 (4.2)
Current 6–20 cigarettes/day 1136 (20.8) 254 (19.9) 150 (17.5) 385 (19.8) 279 (24.9) 68 (26.1)
Current 420 cigarettes/day 311 (5.7) 56 (4.4) 22 (2.6) 97 (5.0) 78 (7.0) 58 (22.2)
Educational level, n (%)
Low 2271 (41.5) 774 (60.2) 376 (43.7)y 674 (34.6)y 342 (30.5)y 105 (40.2)y o0.001
Middle 1431 (26.1) 314 (24.4) 245 (28.5) 536 (27.5) 272 (24.2) 64 (24.5)
High 1774 (32.4) 197 (15.3) 239 (27.8) 739 (37.9) 507 (45.2) 92 (35.2)
Parental history of CKD, n (%) 82 (1.5) 25 (1.9) 11 (1.3) 24 (1.2) 17 (1.5) 5 (1.9) 0.49
History of CVD, n (%) 179 (3.3) 62 (4.8) 20 (2.3)z 61 (3.1)* 32 (2.9)* 4 (1.5)* 0.003
Height (cm) 173.1±9.4 169.6±9.3 171.3±9.0y 174.4±9.2y 175.4±9.1y 176.6±8.7y o0.001
Weight (kg) 77.1±13.5 76.4±14.6 76.2±13.8 77.1±12.8 77.9±13.0z 80.5±13.6y o0.001
Body mass index (kg/m2) 25.7±4.0 26.5±4.7 25.9±4.3y 25.3±3.5y 25.3±3.4y 25.8±3.8z o0.001
Diastolic BP (mmHg) 73±9 73±9 72±9* 72±9 74±9z 77±9y o0.001
Systolic BP (mmHg) 126±18 127±20 125±18 124±17 127±17 131±17 o0.001
Use of BP-lowering drugs, (%) 639 (11.7) 222 (17.3) 95 (11.0)y 192 (9.9)y 100 (8.9)y 30 (11.5)* o0.001
Hypertension, n (%) 1446 (26.4) 414 (32.2) 218 (25.3)z 441 (22.6)y 284 (25.3)y 89 (34.1) 0.004
Total cholesterol (mmol/l) 5.6±1.1 5.6±1.1 5.5±1.2* 5.5±1.1z 5.6±1.1 5.8±1.2z o0.001
HDL-cholesterol (mmol/l) 1.35±0.39 1.30±0.38 1.34±0.4 1.36±0.40y 1.40±0.42y 1.37±0.40* o0.001
Triglycerides (mmol/l) 1.1 (0.8–1.6) 1.2 (0.9–1.7) 1.1 (0.8–1.6)z 1.1 (0.8–1.5) y 1.1 (0.8–1.6) 1.2 (0.9–1.8)z o0.001
Use of lipid-lowering drugs, n (%) 281 (5.1) 91 (7.1) 41 (4.8) 78 (4.0) y 57 (5.1) * 14 (5.4) 0.016
Hypercholesterolemia, n (%) 1586 (29.0) 417 (32.5) 246 (28.6) 509 (26.1)y 323 (28.8) 91 (34.9) 0.15
Glucose (mmol/l) 4.7±0.9 4.8±1.1 4.7±0.9z 4.7±0.7y 4.8±0.9 5.0±0.9 o0.001
HOMA-IR score 1.6 (1.1–2.4) 1.7 (1.2–2.7) 1.7 (1.2–2.5) 1.5 (1.0–2.2)y 1.5 (1.0–2.3)y 1.6 (1.0–2.5) o0.001
Use of glucose-lowering drugs, n (%) 57 (1.0) 28 (2.2) 8 (0.9)* 12 (0.6)y 7 (0.6)z 2 (0.8) o0.001
Type 2 diabetes, n (%) 108 (2.0) 44 (3.4) 15 (1.7)* 21 (1.1)y 20 (1.8)* 8 (3.1) 0.009
C-reactive protein (mg/l) 1.1 (0.5–2.6) 1.4 (0.6–3.1) 1.1 (0.5–2.8)z 0.9 (0.4–2.1)y 1.0 (0.4–2.5)y 1.4 (0.7–3.2) o0.001
Creatinine (mg/dl) 0.80±0.15 0.76±0.15 0.78±0.14 0.81±0.15y 0.82±0.15y 0.82±0.14y o0.001
Cystatin C (mg/l) 0.86 (0.77–0.95) 0.87 (0.78–0.97) 0.86 (0.77–0.95) 0.85 (0.77–0.94)y 0.86 (0.77–0.94)z 0.87 (0.79–0.96) o0.001
eGFR (ml/min per 1.73m2) 97.3±14.8 95.1±15.9 97.2±14.8z 98.3±14.5y 98.0±14.1y 98.2±13.4z o0.001
Urine volume (ml per 24h) 1576±527 1513±540 1568±550* 1572±513z 1631±502y 1714±548y o0.001
Urinary albumin excretion (mg per 24h) 8.0 (5.8–12.3) 8.2 (5.8–12.3) 7.7 (5.7–11.8) 8.2 (6.0–12.0) 8.3 (6.1–12.4) 8.1 (5.9–12.9) 0.221
Abbreviations: BP, blood pressure; CKD, chronic kidney disease; CVD, cardiovascular disease; eGFR, estimated glomerular filtration rate based on a combined
creatinine–cystatin C equation; HDL, high-density lipoprotein; HOMA-IR, homeostatic model assessment-insulin resistance; PREVEND, Prevention of Renal and Vascular End-
Stage Disease; wk, week.
Data are expressed as mean±s.d., median (interquartile range) or proportion n (%).
P-values were based on analysis of variance (nonskewed continuous variables), Kruskal–Wallis test (skewed continuous variables), or w2-test (categorical variables).
Superscripts denote whether a categorical level of alcohol consumption category differs significantly from the categorical level of no alcohol consumption in that row;
*Po0.05, zPo0.01, yPo0.001.
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o60ml/min per 1.73m2 or/and UAE 430mg/24 h). Base-
line alcohol consumption was inversely associated with the
risk of CKD after multivariable adjustment, regardless of
whether CKD was based on eGFR and UAE combined or
based on eGFR or UAE alone (all P-trends are o0.05;
Table 3). There were no material changes in the inverse asso-
ciations after adjustment for potential intermediate variables
of this association, including total to HDL-cholesterol ratio,
the homeostatic model assessment for insulin resistance, and
systolic blood pressure. The results were modestly attenuated
when we controlled for baseline eGFR and UAE in the
multivariable-adjusted model. Compared with nondrinkers,
the hazard ratios (HRs; 95% confidence intervals (CIs))
for CKD risk were 0.95 (0.77–1.17) for occasional, 0.84
(0.71–1.00) for light, 0.77 (0.63–0.95) for moderate, and 0.69
(0.49–0.99) for heavier alcohol consumers (P-trend¼ 0.003).
The inverse association was unchanged when we additionally
accounted for 24-h urinary volume in the multivariable-
adjusted model (P-trendo0.001). The associations between
alcohol consumption and risk of CKD defined according to
creatinine-based or cystatin C–based equations to calculate
eGFR are shown in the Supplementary Table S2 online. The
inverse associations between alcohol consumption and the
risk of CKD were generally similar in analyses stratified by
selected characteristics (Table 4), with no significant inter-
actions by age, sex, smoking, hypertension, or hypercholes-
terolemia (all P-interactions 40.30). Instead of specifying
stratum-specific baseline hazard functions to account for the
sampling design of the study, we also addressed the over-
sampling of subjects with elevated UAE by using design-
based Cox proportional hazards regression models that took
into account the probability of selection by statistical
weighting. This analysis revealed similar results (Figure 1).
Sensitivity analyses
We excluded nondrinkers at baseline to remove the potential
bias due to ‘sick quitters’13 among the nondrinkers. The
multivariable HRs (95% CIs) were 0.95 (0.78–1.17) for light,
0.84 (0.66–1.05) for moderate, and 0.69 (0.49–1.01) for
heavier drinkers compared with occasional drinkers (P-linear
trend¼ 0.025). To further address this potential bias, we
performed a sensitivity analysis starting from the second
examination and added a category of former drinkers to the
original five drinking categories. Compared with subjects
who remained nondrinkers at the second examination, the
multivariable-adjusted HRs (95% CIs) for risk of CKD were
0.68 (0.43–1.09) for former, 0.77 (0.59–1.02) for occasional,
0.73 (0.57–0.94) for light, 0.71 (0.54–0.93) for moderate, and
0.61 (0.40–0.94) for heavier alcohol consumers. Second,
results were essentially the same when we excluded subjects at
baseline with an eGFR o66 (instead ofo60)ml/min per
1.73m2 and/or a UAE 425 (instead of 430)mg per 24 h
for a more pronounced decline in kidney function during
follow-up before reaching the CKD end point. Compared
with nondrinkers, the multivariable-adjusted HRs (95% CIs)
for CKD risk were 0.83 (0.65–1.04) for occasional, 0.80
(0.66–0.97) for light, 0.71 (0.57–0.90) for moderate, and 0.60
(0.41–0.90) for heavier alcohol consumers (P-trend¼ 0.001).
Third, although this may introduce bias toward apparent
health benefits of alcohol consumption because of reducing
alcohol intake with increasing age/frailty, we performed time-
varying Cox regression analyses in which we updated infor-
mation on alcohol consumption and all potential confounders
in the multivariable-adjusted model to allow for changes over
time. The inverse association was not materially influenced
when information on alcohol consumption and confounders
of the multivariable-adjusted model was updated during
follow-up to account for changes over time (Supplementary
Table S3 online).
DISCUSSION
In this prospective population-based cohort study with
repeated measurements of serum creatinine, serum cystatin
C, and 24-h UAE to ascertain CKD, alcohol consumption was
Table 2 | Serum high-density lipoprotein cholesterol concentrations according to self-reported alcohol consumption











n 878 553 916 442 65
Age-adjusted 1.41 (1.38–1.43) 1.45 (1.42–1.48)z 1.56 (1.54–1.59)y 1.65 (1.62–1.69)y 1.64 (1.54–1.73)y o0.001
Multivariable-adjusted 1.43 (1.40–1.45) 1.44 (1.41–1.48)z 1.54 (1.52–1.57)y 1.64 (1.61–1.68)y 1.70 (1.61–1.80)y o0.001
Men
n 394 301 1010 669 193
Age-adjusted 1.08 (1.05–1.11) 1.13 (1.09–1.16)z 1.17 (1.15–1.19)y 1.22 (1.20–1.25)y 1.27 (1.23–1.32)y o0.001
Multivariable-adjusted 1.09 (1.06–1.11) 1.13 (1.09–1.16)z 1.17 (1.15–1.18)y 1.23 (1.20–1.25)y 1.30 (1.26–1.34)y o0.001
Abbreviations: HDL, high-density lipoprotein; wk, week.
Means (95% confidence intervals) and P-values were derived from general linear models. Multivariable-adjusted model was adjusted for age, height, weight, smoking status,
parental history of chronic kidney disease, history of cardiovascular disease, educational level, and serum total cholesterol concentration. Superscripts denote whether the
mean HDL level of a categorical level of alcohol consumption differs significantly from the categorical level of no alcohol consumption in that row; *Po0.05, zPo0.01,
yPo0.001.
P-trend was derived from general linear models by treating alcohol consumption as a continuous linear term.
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inversely associated with the risk of CKD. The lower risk
associated with alcohol consumption was consistent across
different strata of selected CKD risk factors and was apparent
when CKD was defined on the basis of a combination of
eGFR and UAE, and when defined on the basis of either
eGFR or UAE alone. The inverse association between alcohol
intake and risk of CKD remained after adjustment for
confounders, CKD risk factors, and potential mediators of
the association such as of homeostatic model assessment for
insulin resistance, total to HDL-cholesterol ratio, and systolic
blood pressure.
Four prospective observational studies have investigated
the association between alcohol consumption and risk of
CKD (either based on eGFR or albuminuria/proteinuria).3–6
These studies predominantly assessed eGFR with a
creatinine-based MDRD equation, which is derived from
a select population with renal disease8 and has uncertain
validity in cohorts in which eGFR is 460ml/min per
1.73m2.9 Analogous to our findings, inverse associations
between alcohol consumption and risk of CKD were reported
among 11,203 US male physicians3 and 6259 Australian men
and women5, with top alcohol consumption categories of
only 47 drinks/week and 430 g/day, respectively. Alcohol
intake o20 g/day was also inversely associated with CKD
among 41,012 male and 82,752 female Japanese adults, with
no apparent effect of an intake X20 g/day, compared with
abstention.4 Shankar et al.6 reported a more U-shaped
relationship with a borderline increased CKD risk starting
from X4 drinks/day among 3392 participants.
Two longitudinal studies simultaneously examined the
effect of alcohol on new-onset albuminuria or proteinuria,
besides the eGFR-based CKD.4,5 Compared with abstention,
alcohol consumption of o20 g/day was associated with a
decreased risk of developing a positive dipstick proteinuria
in men, with a similar trend in women, during annual
examinations for 10 years among 123,764 Japanese adults.4 In
contrast to these and our findings, and besides an inverse
association with de novo eGFR o60ml/min per 1.73m2,
White et al.5 simultaneously reported a trend toward a
positive association between alcohol consumption and risk of
5-year doubling of the albumin to creatinine ratio (defined as
a final albumin to creatinine ratio 42.5mg/mmol for men
and 3.5mg/mmol for women in the absence of albuminuria
at baseline). The discrepancies may perhaps be explained
by differences in study design. The Prevention of Renal and
Vascular End-Stage Disease (PREVEND) study was speci-
fically designed to examine the effects of albuminuria and has
several repeated measures of two consecutive 24-h urine
collections to determine albuminuria.
In line with our findings on the risk of CKD, alcohol
consumption was inversely associated with the risk of
developing end-stage renal disease among B65,000
Chinese men aged 40–65 years.14 However, kidney
function was not assessed at baseline in this study, and CKD
Table 3 | Association between alcohol consumption and risk of CKD according to different CKD definitions*
Alcohol consumption categories (g of alcohol)













eGFRcreatinine–cystatin C o60ml/min per 1.73m2 or urinary albumin excretion 430mg per 24h
No. of cases (%) 256 (19.9) 137 (15.9) 303 (15.5) 170 (15.2) 37 (14.2)
Person-years 10,827 7616 17,551 10,115 2374
Age- and sex-adjusted HR 1.00 (Ref) 0.83 (0.67–1.02) 0.81 (0.69–0.96)* 0.72 (0.59–0.88)z 0.64 (0.45–0.91)* o0.001
Multivariable-adjusted HR 1.00 (Ref) 0.85 (0.69–1.04) 0.82 (0.69–0.98)* 0.71 (0.58–0.88)z 0.60 (0.42–0.86)z o0.001
Multivariable-adjustedþpotential mediators HR 1.00 (Ref) 0.85 (0.69–1.06) 0.88 (0.74–1.05) 0.76 (0.62–0.94)* 0.58 (0.40–0.84)z 0.002
eGFRcreatinine–cystatin C o60ml/min per 1.73m2
No. of cases (%) 100 (7.8) 50 (5.8) 96 (4.9) 45 (4.0) 9 (3.4)
Person-years 11,570 8183 18,727 10,832 2498
Age- and sex-adjusted HR 1.00 (Ref) 0.80 (0.57–1.13) 0.89 (0.67–1.18) 0.65 (0.46–0.94)* 0.65 (0.33–1.30) 0.030
Multivariable-adjusted HR 1.00 (Ref) 0.79 (0.56–1.12) 0.83 (0.62–1.12) 0.58 (0.40–0.84)z 0.58 (0.29–1.17) 0.005
Multivariable-adjustedþpotential mediators HR 1.00 (Ref) 0.81 (0.57–1.15) 0.85 (0.63–1.15) 0.56 (0.38–0.81)z 0.51 (0.25–1.03) 0.003
Urinary albumin excretion 430mg per 24h
No. of cases (%) 186 (14.5) 106 (12.3) 237 (12.2) 140 (12.5) 28 (10.7)
Person-years 11,621 8181 18,834 10,828 2513
Age- and sex-adjusted HR 1.00 (Ref) 0.86 (0.68–1.10) 0.80 (0.66–0.98)* 0.76 (0.60–0.95)* 0.60 (0.40–0.90)* 0.002
Multivariable-adjusted HR 1.00 (Ref) 0.89 (0.70–1.11) 0.82 (0.67–1.01) 0.76 (0.60–0.96)* 0.57 (0.38–0.85)z 0.002
Multivariable-adjustedþpotential mediators HR 1.00 (Ref) 0.88 (0.69–1.12) 0.89 (0.73–1.10) 0.82 (0.65–1.05) 0.58 (0.38–0.88)* 0.020
Abbreviations: CKD, chronic kidney disease; eGFR, estimated glomerular filtration rate; HR hazard ratio; wk, week.
HR, 95% confidence intervals, and P-values were derived from Cox proportional hazards regression models. Superscripts denote whether the HR of a categorical level of
alcohol consumption differs significantly from the categorical level of no alcohol consumption in that row; *Po0.05, zPo0.01. Multivariable adjustment included age,
sex, height, weight, smoking status, parental history of CKD, history of cardiovascular disease, and educational level. Potential mediators were homeostatic model
assessment-insulin resistance, use of glucose-lowering drugs, ratio of total to high-density lipoprotein cholesterol, use of lipid-lowering drugs, systolic blood pressure, and
use of blood pressure–lowering drugs.
P-trend was derived from Cox proportional hazards regression models by treating alcohol consumption as a continuous linear term.
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could have already been present in those who developed end-
stage renal disease. Such patients are more likely to have
reduced or ceased consumption of alcohol, which could have
biased the results toward apparent health benefits of alcohol
consumption.
Studies looking specifically at alcohol consumption and
kidney function decline instead of CKD have generally
reported no effects or, if any, beneficial effects. Among 1658
nurses with an initial eGFR of B90ml/min per 1.73m2,
there was no association between alcohol consumption and
different percentages of decline in an MDRD-based eGFR
assessed at baseline and after 11 years.15 During a 7-year
follow-up of 4441 Norwegians,46 units of alcohol/week was
associated with an increase in MDRD-based eGFR compared
with abstention, but only in men and not in women.16
Alcohol intake was not associated with rapid kidney function
decline (defined as an annual decline43ml/min per 1.73m2
in a cystatin C–based eGFR) among 4343 subjects, aged465
years, of the Cardiovascular Health Study.17 However, alcohol
consumption categories did show a positive association with
the cystatin C–based eGFR at baseline.
The number of participants reporting heavier alcohol
consumption (430 g of alcohol/day) in our study was
relatively low, and findings related to this group should be
interpreted with appropriate caution. Moreover, the range of
overall alcohol consumption reported by these subjects
was truncated, limiting our ability to define potentially
detrimental effects of heavy drinking. Clearly, the observa-
tions for heavier drinkers must be considered in light of the
deleterious effects of excessive alcohol intake, given the well-
documented harmful effects that alcohol can cause when
consumed in excess.18,19 Heavy or excessive drinking should
always be discouraged, whereas light to moderate alcohol
Table 4 | Hazard ratios (95% confidence intervals) for stratified analyses of the association between alcohol consumption and
risk of CKD*











o58 1.00 (Ref) 0.90 (0.67–1.22) 0.88 (0.69–1.14) 0.76 (0.57–1.02) 0.59 (0.36–0.94)* 0.009 0.98
X58 1.00 (Ref) 0.79 (0.59–1.06) 0.76 (0.59–0.98)* 0.69 (0.51–0.93)* 0.68 (0.40–1.17) 0.005
Sex
Male 1.00 (Ref) 1.00 (0.68–1.29) 0.98 (0.72–1.18) 0.84 (0.64–1.10) 0.69 (0.45–1.05) 0.06 0.76
Female 1.00 (Ref) 0.76 (0.57–1.01) 0.68 (0.53–0.89) 0.61 (0.43–0.86) 0.56 (0.27–1.17) 0.001
Smoking
Never 1.00 (Ref) 0.86 (0.61–1.23) 0.74 (0.53–1.05) 0.52 (0.31–0.88)* 0.51 (0.18–1.40) 0.007 0.71
Former/current 1.00 (Ref) 0.83 (0.64–1.08) 0.84 (0.69–1.03) 0.77 (0.61–0.97)* 0.67 (0.46–0.98)* 0.013
Hypertension
No 1.00 (Ref) 0.94 (0.70–1.26) 0.89 (0.69–1.14) 0.75 (0.56–1.00)* 0.68 (0.42–1.10) 0.03 0.86
Yes 1.00 (Ref) 0.79 (0.59–1.05) 0.79 (0.61–1.01) 0.70 (0.52–0.94) 0.51 (0.30–0.87)* 0.003
Hypercholesterolemia
No 1.00 (Ref) 0.97 (0.74–1.27) 0.79 (0.63–1.00)* 0.74 (0.57–0.97)* 0.63 (0.40–0.99)* 0.004 0.30
Yes 1.00 (Ref) 0.69 (0.49–0.94)* 0.90 (0.68–1.17) 0.67 (0.48–0.94)* 0.54 (0.30–0.95)* 0.017
Abbreviations: CKD, chronic kidney disease; eGFR, estimated glomerular filtration rate; wk, week.
Hazard ratios, 95% confidence intervals, and P-values were derived from Cox proportional hazards regression models and were adjusted for age, sex, height, weight,
smoking status, parental history of CKD, history of cardiovascular disease, and educational level. Superscripts denote whether the hazard ratio of a categorical level of
alcohol consumption differs significantly from the categorical level of no alcohol consumption in that row; *Po0.05. CKD was defined as eGFRcreatinine–cystatin C o60ml/min
per 1.73m2 or urinary albumin excretion 430mg per 24h.
P-trend was derived by treating alcohol consumption as a continuous linear term.
P-interaction was derived by using a likelihood ratio test from models with and without the cross-product term of alcohol category (nondrinker, occasional, light, moderate,




























Figure 1 | Association between alcohol consumption and risk of
chronic kidney disease (CKD). Hazard ratios (HRs; error bars indicate
95% confidence interval) were adjusted for age, sex, height, weight,
smoking status, parental history of CKD, history of cardiovascular
disease, and educational level, and were derived from a Cox
proportional hazards regression model using complex sampling to
account for the sampling design of the study (presence or absence of
an urinary albumin concentration of 410mg/l) by statistically
weighing the probability of selection. CKD was defined as
creatinine–cystatin C–based estimated glomerular filtration rate
o60ml/min per 1.73m2 or urinary albumin excretion 430mg per
24 h. P-trend o0.001. Wk, week.
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consumption may be regarded as a complement to other
lifestyle habits for reducing the risk of CKD.20
The mechanisms by which alcohol consumption may
influence the risk of CKD remain unclear. In clinical trials,
moderate alcohol consumption increases insulin sensitivity21,22
and serum HDL-cholesterol.23,24 Nevertheless, the alcohol-
CKD association remained after accounting for homeostatic
model assessment for insulin resistance and total to HDL-
cholesterol ratio, although both measures may be imperfect
reflections of insulin sensitivity and (systemic) atherosclerosis,
respectively. Alcohol acutely increases urine production, most
likely through inhibition of the release of arginine vasopressin
(antidiuretic hormone).25 This increased flow has been the
putative mechanism through which alcohol may lower the risk
of renal cell carcinoma.26,27 We, however, found no evidence
that the mean of two 24-h urine volumes—a fairly poor proxy
of long-term urine production—influenced the association
between habitual alcohol consumption and risk of CKD.
The potential limitations of our study should be consi-
dered. We could not distinguish between life-long abstainers
and former drinkers, including potential ‘sick quitters’ in the
nondrinkers category at baseline. It is possible that those who
did not drink alcohol at baseline did so owing to health
concerns or increasing frailty. This has been termed the ‘sick
quitter’ hypothesis.13 However, alcohol consumption was also
inversely associated with the risk of CKD in analyses that
excluded all nondrinkers at baseline or that accounted for
former drinkers during follow-up. It is thus unlikely that our
findings can be explained by this hypothesis. Second, we did
not have information on beverage type (e.g., wine, beer, or
spirits) consumed, although both controlled feeding trials
on biomarkers,23,24 and observational cohort studies on
other outcomes do not support beverage-specific
associations.28,29 Third, the daily amounts of alcohol
consumed by women in the moderate category (10–30 g)
were possibly higher than what is considered ‘moderate’ for
women (B15 g in the United States and 16–24 g in the United
Kingdom). These guidelines, however, are directed at
prevention of all chronic diseases rather than on the
maximum risk reduction of CKD. Finally, our findings are
observational and residual or unmeasured confounding may
be present, despite the variety of potentially confounding
factors for which we adjusted.
Major strengths of the study are the serial screenings for
CKD during follow-up and the combined CKD end point
consisting of a creatinine–cystatin C–based eGFR and two
consecutive 24-h UAE at each screening to ascertain CKD
events. An additional strength is the association between self-
reported alcohol consumption categories and HDL-choles-
terol in our study, consistent with the dose–response relation-
ship of alcohol on this biomarker in randomized controlled
trials.23,24 This validated the accuracy of recall and the rank
order of the alcohol categories, although the actual amount
of alcohol consumed may be subject to underreporting.30
Another strength is the consistency of the association across
different strata of risk factors, across different CKD end point
definitions, and in several sensitivity analyses, which all add
to the plausibility of our findings. Finally, the updated
information on alcohol intake during follow-up enabled us to
account for potential changes in drinking habits. Similar to
previous studies on kidney function3,15 or other outcomes,31
alcohol consumption in our study was fairly stable over time.
In this prospective cohort of men and women, alcohol
consumption was consistently inversely associated with the
risk of CKD. Advice concerning alcohol consumption to
lower the risk of CKD should consider the full range of
benefits and risks, including the consistent harm effects of
drinking that exceeds recommended limits. In light of these
potential detrimental health effects, it would be premature to
draw any firm clinical recommendations regarding alcohol
consumption to reduce the risk of CKD. Nevertheless, the
current study finds no grounds to discourage light to moderate
alcohol consumption, at least in terms of its renal effects.
MATERIALS AND METHODS
Study design and population
The PREVEND study is a prospective investigation of albuminuria,
renal, and cardiovascular disease in a large cohort drawn from the
general population. Details of this study are described elsewhere.32,33
In summary, from 1997 to 1998, all inhabitants of Groningen, the
Netherlands, aged 28–75 years (n¼ 85,421), were sent a question-
naire and a vial to collect a first-morning void urine sample.
Pregnant women and subjects with type 1 diabetes mellitus were
excluded. The urinary albumin concentration was assessed in 40,856
responders. Subjects with a urinary albumin concentrationX10mg/l
(n¼ 7768) were invited to participate, of whom 6000 were enrolled.
In addition, a randomly selected group with a urinary albumin
concentrationo10mg/l (n¼ 3394) was invited to participate in the
cohort, of whom 2592 were enrolled. The PREVEND study has been
approved by the medical ethics committee of the University Medical
Center Groningen. Written informed consent was obtained from all
participants. These 8592 individuals form the PREVEND cohort.
We excluded subjects with missing data on alcohol consumption
(n¼ 43), serum creatinine, serum cystatin, or UAE (n¼ 498), with
CKD at baseline (n¼ 1393), or with no follow-up data on kidney
function (n¼ 1182), leaving 5476 participants for the analyses. Of
these, 5417 participants completed a second examination between
2001 and 2003, 4656 participants completed a third examination
between 2003 and 2006, 4092 participants completed a fourth exa-
mination between 2006 and 2008, and 3004 participants completed
a fifth examination between 2008 and 2012.
Data collection
The procedures at each examination in the PREVEND study have
been described in detail previously.34 In brief, each of the examina-
tions included two visits to an outpatient clinic separated by 3 weeks.
Before the first visit, all participants completed a self-administered
questionnaire regarding demographics, cardiovascular and renal
disease history, smoking habits, alcohol consumption, and medica-
tion use. Information on medication use was combined with infor-
mation from a pharmacy-dispensing registry, which has complete
information on drug use of 495% of subjects in the PREVEND
study. Height and weight were measured on the first visit. During
each examination and during each visit, blood pressure was mea-
sured on the right arm, every minute for 10 and 8min, by an
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automatic Dinamap XL Model 9300 series device (Johnson-Johnson
Medical, Tampa, Florida, USA). The mean of the last two recordings
from each of the two visits was used. In the last week before the
second visit, subjects had to collect two consecutive 24-h specimens
after thorough oral and written instruction. During the urine
collection, the participants were asked to avoid heavy exercise as
much as possible. Subjects were also instructed to postpone the
urine collection in case of urinary tract infection, menstruation, or
fever. The collected urine was stored cold (4 1C) for a maximum of 4
days before the second visit. After handing in the urine collections,
the urine specimens were stored at  20 1C. Furthermore, fasting
blood samples were provided and stored at  80 1C.
Assessment of alcohol consumption
Information about alcohol consumption was collected at baseline
and during every follow-up examination. Answer categories included
the following: no/rarely, 1–4 drinks/month, 2–7 drinks/week,
1–3 drinks/day, and 4 or more drinks/day. A standard serving size
of an alcoholic beverage in the Netherlands is equivalent to 10 g of
alcohol, regardless of the beverage type (e.g., beer (250ml), wine
(100ml), or liquor (35ml)).35 We labeled the five categories as
nondrinkers, occasional drinkers (o10 g/week), light drinkers
(10–69.9 g/week), moderate drinkers (70–210 g/week), and heavy
drinkers (4210 g/week).
CKD ascertainment
The primary outcome of CKD was defined as a combination of an
eGFR o60ml/min per 1.73m2 and/or an UAE 430mg per 24 h.
We estimated GFR with the combined creatinine cystatin C–based
Chronic Kidney Disease Epidemiology Collaboration equation from
2012, taking into account age, sex, and race.11 The urinary albumin
concentration was multiplied by urine volume to obtain a value in
mg per 24 h. The two 24-h urinary albumin values of each subject
per examination were averaged.
Measurement of serum creatinine was performed by an enzyma-
tic method on a Roche Modular analyzer using reagents and calibra-
tors from Roche (Roche Diagnostics, Mannheim, Germany), with
intra- and interassay coefficients of variation of 0.9% and 2.9%,
respectively. Serum cystatin C concentrations were measured by
Gentian Cystatin C Immunoassay (Gentian AS, Moss, Norway) on a
Modular analyzer (Roche Diagnostics). Cystatin C was calibrated
directly using the standard supplied by the manufacturer (traceable
to the International Federation of Clinical Chemistry Working
Group for Standardization of Serum Cystatin C).36 The intra- and
interassay coefficients of variation wereo4.1% ando3.3%, respec-
tively. Urinary albumin concentration was measured by nephelometry
with a threshold of 2.3mg/l, and intra- and interassay coefficients of
variation of 2.2% and 2.6%, respectively, (Dade Behring Diagnostic,
Marburg, Germany).
Assessment of covariables
Smoking status was defined as self-reported never smoker, former
smoker, or current smoker (o6, 6–20, or 420 cigarettes/day).
Parental history of CKD was defined as having a first-degree relative
who had a renal disease requiring dialysis for46 weeks. Educational
level was defined as low (primary education or intermediate voca-
tional education), middle (higher secondary education), and high
(higher vocational education and university). Hypertension was
defined as a systolic blood pressure X140mmHg, a diastolic blood
pressure X90mmHg, or the use of blood pressure–lowering drugs.
Concentrations of total cholesterol, HDL-cholesterol, insulin,
glucose, triglycerides, and C-reactive protein were measured using
standard methods, as previously described.37 Hypercholesterolemia
was defined as a total cholesterolX6.21mmol/l, or the use of lipid-
lowering drugs. The homeostatic model assessment for insulin
resistance was calculated as (fasting serum insulin (in mU/l)fasting
serum glucose (in mmol/l))/22.5.38
Statistical analysis
Baseline characteristics are presented according to alcohol con-
sumption categories. Continuous data are presented as mean
with s.d. or as median and interquartile range in case of skewed
distribution. Categorical data are presented as percentiles. To
validate the self-reported alcohol consumption categories, the
association between alcohol consumption and serum HDL-choles-
terol levels was examined using general linear models. These
analyses were stratified by sex because of the differences in serum
HDL-cholesterol levels between men and women.
To examine the prospective association between baseline alcohol
consumption and risk of CKD, analyses were performed using Cox
proportional hazards regression models to calculate the HRs and
95% CIs for each alcohol consumption category using nondrinkers
as reference category. All models took into account the sampling
design of the study (presence or absence of a urinary albumin
concentration 410mg/l) by specifying stratum-specific baseline
hazard functions. In these proportional hazards regression models,
person-time was counted from the date of the first examination
until the date that CKD was diagnosed, or the date of the last exami-
nation, whichever came first. The multivariable-adjusted model
included age, sex, height, weight, smoking status, parental history of
CKD, history of cardiovascular disease, and educational level.
Possible effect modification was explored by including an interac-
tion term for alcohol consumption and effect modifier (age, sex,
smoking, hypertension, and hypercholesterolemia) in the multi-
variable-adjusted model. Instead of specifying stratum-specific
baseline hazard functions, we additionally addressed the over-
sampling of subjects with elevated UAE by using design-based Cox
proportional hazards regression models that took into account the
probability of selection by statistical weighting. This statistical
weighting method allows results to be extrapolated to the general
population. We calculated P-trends by treating the ordinal alcohol
consumption categorical variable as a continuous linear term to use
all the intra-categorical information that is otherwise ignored by
mere categorical comparisons.39
We performed several sensitivity analyses to examine the robu-
stness of the alcohol-CKD association. First, the abstaining category
may include people who have quit drinking owing to ill health or
who may have other preexisting health conditions, which preclude
drinking.13 To investigate whether these factors may account for the
association with alcohol and CKD, we explored the association
among alcohol consumers and excluded abstainers at baseline. In
addition, we performed an analysis starting from the second exami-
nation and added a former drinker category (i.e., subjects who reported
to consume alcohol at the first but not at the second examination)
to the original five alcohol drinking categories. Second, we excluded
subjects at baseline with an eGFRo66 (instead ofo60)ml/min per
1.73m2 and/or a 24-h UAE425 (instead of430) mg per 24 h for a
more pronounced decline in kidney function in order to reach the
primary outcome of CKD. Third, although this may also introduce
bias toward apparent health benefits of alcohol consumption
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because of reducing alcohol intake owing to increasing age/frailty,
we performed a time-varying Cox regression analysis in which we
updated information on alcohol consumption and all confounders
in the multivariable-adjusted model to allow for changes (e.g., in
alcohol drinking habits) over time.
All P-values are two-tailed, and P-values o0.05 were considered
statistically significant. All analyses were conducted with the use of the
statistical package IBM SPSS (version 22.0; IBM, Chicago, IL, USA).
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